Rubicon Research Intrinsic Value
RUBICON • Healthcare
Current Stock Price
₹774.85
Primary Intrinsic Value
₹307.12
Market Cap
₹1162 Cr
-6.9%
Downside
Median Value
₹721.33
Value Range
₹232 - ₹1550
Assessment
Trading Near Calculated Value
Safety Margin
-7.4%
RUBICON Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹307.12 | ₹245.70 - ₹368.54 | -60.4% | EPS: ₹13.96, Sector P/E: 22x |
| Book Value Method | asset | ₹721.33 | ₹649.20 - ₹793.46 | -6.9% | Book Value/Share: ₹360.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1549.70 | ₹1394.73 - ₹1704.67 | +100.0% | Revenue/Share: ₹1101.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1549.70 | ₹1394.73 - ₹1704.67 | +100.0% | EBITDA: ₹380.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1439.83 | ₹1151.86 - ₹1727.80 | +85.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹232.45 | ₹209.20 - ₹255.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹232.45 | ₹209.20 - ₹255.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1549.70 | ₹1394.73 - ₹1704.67 | +100.0% | ROE: 39.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹336.58 | ₹302.92 - ₹370.24 | -56.6% | EPS: ₹13.96, BVPS: ₹360.67 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
RUBICON Intrinsic Value Analysis
What is the intrinsic value of RUBICON?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Rubicon Research (RUBICON) is ₹721.33 (median value). With the current market price of ₹774.85, this represents a -6.9% variance from our estimated fair value.
The valuation range spans from ₹232.45 to ₹1549.70, indicating ₹232.45 - ₹1549.70.
Is RUBICON undervalued or overvalued?
Based on our multi-method analysis, Rubicon Research (RUBICON) appears to be trading near calculated value by approximately 6.9%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.57 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 39.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 23.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.14x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Rubicon Research
Additional stock information and data for RUBICON
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹159 Cr | ₹127 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹21 Cr | ₹-13 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹-75 Cr | ₹-91 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-63 Cr | ₹-86 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹62 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |